New forces are joining in the battle against the new coronavirus outbreak. Regeneron Pharmaceuticals Inc. and the US Department of Health and Human Services (HHS) are expanding a collaboration to include 2019-nCoV, given that Regeneron’s REGN-EB3 has demonstrated effectiveness against the Ebola virus.
REGN-EB3, an combination therapy comprising three antibodies, has been granted US Breakthrough Therapy designation and Regeneron has filed a rolling...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

